The Direct and Indirect Costs among U.S. Privately Insured Employees with Hypogonadism

Journal of Sexual Medicine

Volumn 9, Issue 9, 2012, Pages 2438-2447

  Kaltenboeck, Anna ^a   Foster, Shonda ^b   Ivanova, Jasmina ^a   Diener, Melissa ^a   Bergman, Rachel ^a   Birnbaum, Howard ^a   Kinchen, Kraig ^b   Swindle, Ralph ^b  

^a ANALYSIS GROUP   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Cost of Illness; Economic and Quality of Life Burden; Hypogonadism; Resource Use; Testosterone Deficiency

Indexed keywords

PRESCRIPTION DRUG; TESTOSTERONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BACKACHE; COMORBIDITY; CONTROLLED STUDY; DISABILITY; EMPLOYEE; HEALTH CARE COST; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERLIPIDEMIA; HYPERTENSION; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; NECK PAIN; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RISK ASSESSMENT; UNITED STATES;

EID: 84865795133     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2012.02810.x     Document Type: Article

References (19)

1. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59.
2. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: The HIM study. Int J Clin Pract 2006;60:762-9.
3. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241-7.
4. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry 2004;61:162-7.
5. Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001;22:793-7.
6. Rosen RC, Araujo AB, Connor MK, Elstad EA, McGraw SA, Guay AT, Morgentaler A, Miner MM. Assessing symptoms of hypogonadism by self-administered questionnaire: Qualitative findings in patients and controls. Aging Male 2009;12:77-85.
7. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M. Testosterone and metabolic syndrome: A meta-analysis study. J Sex Med 2011;8:272-83.
8. Lin JW, Lee JK, Wu CK, Caffrey JL, Chang MH, Hwang JJ, Dowling N, Lin YS. Metabolic syndrome, testosterone, and cardiovascular mortality in men. J Sex Med 2011;8:2350-60.
9. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002;3:377-84.
10. Aloisi AM, Aurilio C, Bachiocco V, Biasi G, Fiorenzani P, Pace MC, Paci V, Pari G, Passavanti G, Ravaioli L, Sindaco G, Vellucci R, Ceccarelli I. Endocrine consequences of opioid therapy. Psychoneuroendocrinology 2009;34S:S162-8.
11. Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, Verlooy J, Van Havenbergh T, Smet M, Van Acker K. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000;85:2215-22.
12. Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med 2011;8:639-54.
13. Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, Schulman C, Tan HM, Torres LO, Yassin A, Zitzmann M. Endocrine aspects of male sexual dysfunctions. J Sex Med 2010;7:1627-56.
14. Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FC. Testosterone replacement therapy: Current trends future directions. Hum Reprod Update 2004;10:409-19.
15. Haring R, Baumeister SE, Völzke H, Kohlmann T, Marschall P, Flessa S, Nauch M, Wallaschofski H. Prospective association of low serum total testosterone levels with health care utilization and costs in a population-based cohort of men. Int J Androl 2009;33:1-10.
16. Barrett-Connor E, von Mühlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: The Rancho Bernardo study. J Clin Endocrinol Metab 1999;84:573-7.
17. Maggi M, Schulman C, Quinton R, Langham S, Uhl-Hochgraeber K. The burden of testosterone deficiency syndrome in adult men: Economic and quality-of-life impact. J Sex Med 2007;4:1056-69.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83.
19. Romano PS, Roos LL, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1993;46:1075-9.